Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $1.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +32.00%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.04 per share when it actually produced a loss of $1.06, delivering a surprise of -1.92%.Over the last four quarters, ...